Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Immunicon Corporation, a company developing and commercializing proprietary cell- and molecular-based human diagnostic and life science research products with an initial focus on cancer disease management, has entered into two separate agreements with AstraZeneca
Subscribe to our email newsletter
The first of these agreements is focused on the development of methodologies to identify and quantify certain cell types circulating in blood that are potentially valuable biomarkers for targeted therapies.
In a second agreement, Immunicon will perform laboratory services in connection with various drug development programs in the fields of cancer and infectious diseases. Immunicon will provide enumeration and characterization of circulating tumor cells and circulating endothelial cells as well as certain molecular characterization of these rare cells.
“We are very pleased to enter into these collaborations with AstraZeneca. We hope that the new assays that we plan to develop under the research agreement will help to accelerate AstraZeneca’s therapy development by assessing the presence of their treatment targets and earlier determination of the effectiveness of these therapies,” said Leon Terstappen, chief scientific officer of Immunicon.